tiprankstipranks
Trending News
More News >

Abbisko Therapeutics to Present Promising Phase 2 Study Results at ESMO GI Congress

Story Highlights
  • Abbisko Therapeutics will present phase 2 study results of irpagratinib for HCC at the 2025 ESMO GI Congress.
  • The study shows promising efficacy of irpagratinib with atezolizumab, highlighting potential market impact.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Abbisko Therapeutics to Present Promising Phase 2 Study Results at ESMO GI Congress

Don’t Miss TipRanks’ Half-Year Sale

The latest announcement is out from Abbisko Cayman Limited ( (HK:2256) ).

Abbisko Therapeutics announced that it will present updated results from its phase 2 study of irpagratinib in combination with atezolizumab for advanced hepatocellular carcinoma (HCC) at the 2025 ESMO GI Congress. The study highlights a significant objective response rate and median progression-free survival, indicating the potential efficacy of this combination therapy for HCC patients, especially those with FGF19 overexpression. This development underscores Abbisko’s commitment to advancing cancer treatment options and could have implications for its market positioning and stakeholder interests.

The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.

More about Abbisko Cayman Limited

Abbisko Cayman Limited, through its subsidiary Abbisko Therapeutics, operates in the biopharmaceutical industry, focusing on the development of innovative therapies for cancer treatment. The company is particularly involved in researching and developing combination therapies for hepatocellular carcinoma (HCC) and other cancers, aiming to improve patient outcomes with novel treatment strategies.

Average Trading Volume: 5,452,665

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.15B

See more data about 2256 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1